FrancophonIA/ELRC3.0 huggingface dataset:
English: The Applicant/MAH had conducted further analysis and validation in support of the in-process and finished product testing specifications, which could be considered adequate, provided some points of clarification were adequately addressed.
Slovenian: Predlagatelj/imetnik dovoljenja za promet z zdravilom je opravil dodatno analizo in potrditev v podporo specifikacijam medprocesnih preskusov in preskusov končnega zdravila, ki se lahko šteje za zadostno ob upoštevanju, da so bile nekatere točke ustrezno pojasnjene.
English: ANNEX III CONDITIONS FOR THE LIFTING OF THE MARKETING AUTHORISATION SUSPENSION
Slovenian: DODATEK III POGOJI ZA PREKLIC ZADRŽANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM
English: However, whilst these provided more detailed information than had been previously available these were not sufficient to confirm the validity of the studies for the purposes of supporting a efficacy claim for P.multocida.
Slovenian: Čeprav so ta dala podrobnejše podatke od tistih, dostopnih pred tem, pa niso bila zadostna za potrditev veljavnosti študij za podporo trditve o učinkovitosti komponente P. multocida.
English: Concerns over A.pleuropneumoniae efficacy related to a lack of confirmation of Apx toxins in the finished product and absence of specific challenge studies with APP serotype 11.
Slovenian: Zadržki glede učinkovitosti komponente A. pleuropneumoniae so se pojavili, ker ni niti potrditve prisotnosti toksinov Apx v končnem zdravilu niti specifičnih izzivnih študij z APP serotipa 11.
English: ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR REFUSAL OF THE GRANTING OF THE MARKETING AUTHORISATIONS AND FOR THE SUSPENSION OF EXISTING MARKETING AUTHORISATION
Slovenian: DODATEK II ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA ZAVRNITEV ODOBRITVE DOVOLJENJA ZA PROMET Z ZDRAVILOM IN ZADRŽANJE OBSTOJEČEGA DOVOLJENJA ZA PROMET Z ZDRAVILOM
English: In view of the fact that Serotypes 9 and 11 belong to the same toxigenic group (Group 1, producing Apx1 and Apx2) and Serotype 2 belongs to Toxigenic Group 2, producing Apx2 and Apx3, then this Ph. Eur.
Slovenian: Glede na to, da serotipa 9 in 11 spadata v isto toksigensko skupino (skupina 1, ki tvori Apx1 in Apx2), serotip 2 pa v toksigensko skupino 2, ki tvori Apx2 in Apx3, se ta zahteva Ph. Eur.
English: The major point of refusal related to the lack of evidence to support the efficacy of the P.multocida component.
Slovenian: Poglavitna točka zavrnitve se je nanašala na pomanjkanje dokazov v podporo učinkovitosti komponente P. multocida.
English: Pasteurella multocida serotype A ≥ 2'1 log2 (*)
Slovenian: Pasteurella multocida serotip A ≥ 2'1 log2 (*)
English: The Applicant considers that the pathological changes seen in the lungs are different due to Actinobacillus pleuropneumoniae compared to Pasteurella multocida.
Slovenian: Predlagatelj meni, da se patološke spremembe zaradi Actinobacillus pleuropneumoniae v pljučih razlikujejo od sprememb zaradi Pasteurella multocida.
English: In view of the fact that the Applicant/MAH proposed to support the efficacy of the P. multocida component with data from the field the Applicant/MAH was requested to clarify whether animals vaccinated with APPM Respipharm, competitor vaccine and unvaccinated controls had been housed together on each site, which could have allowed a valid comparison of the efficacy of the respective vaccines.
Slovenian: Ker je predlagatelj/imetnik dovoljenja za promet z zdravilom predlagal podporo učinkovitosti komponente P. multocida s terenskimi podatki, je bil naprošen, da pojasni, ali so bile živali, cepljene s cepivom APPM Respipharm, konkurenčnim cepivom, in necepljene živali na vsaki lokaciji nastanjene skupaj, kar bi omogočilo veljavno primerjavo učinkovitosti cepiv.
English: For immunization of sows the first dose (3ml) should be given 4-5 weeks before the expected farrowing date, with the second injection (3ml) at least 2 weeks before the expected farrowing date.
Slovenian: Za imunizacijo svinj je treba prvi odmerek (3 ml) dati 4-5 tednov pred pričakovano kotitvijo, drugo injekcijo (3 ml) pa najmanj 2 tedna pred pričakovano kotitvijo.
English: There were concerns as to how the results had been assessed, in particular how mortality and lung confiscations had been definitively assigned to A.pleuropneumoniae.
Slovenian: Izraženi so bili zadržki o vrednotenju rezultatov, zlasti o gotovosti pripisa smrtnosti in pljučnih zapletov bakterijama A. pleuropneumoniae.
English: The analysis had looked at the frequency of mortality and lung confiscations at slaughter (indicative of the presence of lesions) caused by either APP or P.multocida in pigs vaccinated with APPM Respipharm.
Slovenian: V analizi so pregledali smrtnost in pogostnost zaplemb pljuč pri zakolu (ki so kazale prisotnost lezij) zaradi APP ali P. multocida pri prašičih, cepljenih s cepivom APPM Respipharm.
English: Consequently, there were concerns that batch to batch consistency could not be ensured.
Slovenian: Posledično so se pojavili zadržki glede zagotovitve doslednosti med serijami.
English: The Applicant/MAH provided information on the antigen content of the batches of vaccine used in the field studies.
Slovenian: Predlagatelj/imetnik dovoljenja za promet z zdravilom je predložil podatke o vsebnosti antigena v serijah cepiva, uporabljenih v terenskih študijah.
English: The Applicant/MAH confirmed that the diagnosis was conducted by experienced veterinary practitioners based on previous clinical history and on post mortem findings in cases of mortality.
Slovenian: Predlagatelj/imetnik dovoljenja za promet z zdravilom je potrdil, da so diagnoze postavljali izkušeni veterinarji na podlagi klinične anamneze in ugotovitev obdukcij v primeru smrti živali.
English: Concerning the link to the efficacy of P.multocida the Applicant/MAH was requested to provide further information on the batches of vaccine used during the field studies and further clarification on the details of the studies sufficient to substantiate a claim for the efficacy of the P.multocida component.
Slovenian: Predlagatelj/imetnik dovoljenja za promet z zdravilom je bil glede povezave z učinkovitostjo komponente P. multocida naprošen, da predloži dodatne podatke o serijah cepiva, ki so bile uporabljene v terenskih študijah, ter dodatno pojasnilo o podrobnostih študije, ki so zadostovale za utemeljitev trditve o učinkovitosti komponente P. multocida.
English: The applicant provided field data, supplemented with bibliographical data, to indicate that P.multocida causes frequent co-infections with APP in pigs with respiratory disease.
Slovenian: Predlagatelj je predložil terenske podatke, dopolnjene z bibliografskimi podatki, za prikaz, da P. multocida povzroča pogoste okužbe sočasno z APP pri prašičih z boleznimi dihal.
English: - the CVMP considered that these deficiencies are such that it is considered that no data have been provided in support of the efficacy of the P. multocida serotype A component.
Slovenian: - CVMP šteje, da je posledica teh pomanjkljivosti, da ni predloženih podatkov v podporo učinkovitosti komponente P. multocida serotipa A.
English: Concerning the surveillance field study the Applicant/MAH gave additional data about the batches used, which were by mistake omitted.
Slovenian: V zvezi s terensko študijo spremljanja organizmov je predlagatelj/imetnik dovoljenja za promet z zdravilom predložil dodatne podatke o uporabljenih serijah, ki so bili pomotoma izpuščeni.
English: Whereas: - the CVMP considered that there are significant deficiencies in the data provided by the Applicant in support of the efficacy of the Pasteurella multocida serotype A component.
Slovenian: - CVMP je menil, da obstajajo pomembne pomanjkljivosti v podatkih, ki jih je predlagatelj predložil v podporo učinkovitosti komponente Pasteurella multocida serotipa A.
English: Regarding justification of the P. multocida component in the vaccine the Applicant/MAH has provided field data from a surveillance study, supplemented with bibliographical data, to indicate that P.multocida causes frequent co-infections with APP in pigs with respiratory disease.
Slovenian: Predlagatelj/imetnik dovoljenja za promet z zdravilom je v zvezi z utemeljitvijo komponente P. multocida v cepivu predložil terenske podatke iz študije spremljanja organizma, dopolnjene z bibliografskimi podatki, za prikaz, da P. multocida povzroča pogoste okužbe sočasno z APP pri prašičih z boleznimi dihal.
English: The Applicant/MAH clarified the composition of the other comparator products and confirmed that they had been administered according to the recommended schedule.
Slovenian: Predlagatelj/imetnik dovoljenja za promet z zdravilom je pojasnil sestavo primerjalnih cepiv ter potrdil, da so bila cepiva uporabljena po priporočenem režimu.
English: In addition, field data were presented comparing the clinical outcome in pigs with respiratory disease on farms where APP and P.multocida are simultaneously present, and which have been vaccinated with either APPM Respipharm or a competitor product incorporating APP only.
Slovenian: Poleg tega so bili predloženi terenski podatki za primerjavo kliničnega izida pri prašičih z boleznijo dihal na kmetijah, kjer sta bila sočasno prisotna APP in P. multocida, in prašičih, ki so bili cepljeni bodisi s cepivom APPM Respipharm ali konkurenčnim cepivom, ki vsebuje le APP.
English: The justification to include the P.multocida component in the vaccine had been accepted by the Committee during the referral procedure.
Slovenian: Odbor je med napotitvenim postopkom sprejel utemeljitev vključitve komponente P. multocida v cepivo.
English: In addition, field data have been accumulated comparing the clinical outcome in pigs with respiratory disease on farms where APP and P.multocida are simultaneously present, and which have been vaccinated with either APPM Respipharm or a competitor product incorporating APP only.
Slovenian: Poleg tega so bili zbrani terenski podatki za primerjavo kliničnega izida pri prašičih z boleznijo dihal na kmetijah, kjer sta bila sočasno prisotna APP in P. multocida, in prašičih, ki so bili cepljeni bodisi s cepivom APPM Respipharm ali konkurenčnim cepivom, ki vsebuje le APP.
English: The Note for Guidance on requirements for combined veterinary vaccines2, states “Deletion of challenges is only acceptable in rare cases and must be fully justified.”, and in addition Annex I to Directive 2001/82/EC as amended (Part 4 Efficacy tests, Field trials), which states that “Where laboratory trials cannot be supportive of efficacy, the performance of field trials alone may be acceptable.”.
Slovenian: Poleg tega pa Dodatek I k Direktivi 2001/82/ES, kakor je bila spremenjena (4. del: Preskusi učinkovitosti, Preskušanja na terenu), določa naslednje: „Če laboratorijski preskusi ne dokazujejo učinkovitosti, je lahko sprejemljiva tudi samo izvedba terenskih preskušanj.“.
English: Actinobacillus pleuropneumoniae serotype 9 ≥ 5,2 log2 (*)
Slovenian: Actinobacillus pleuropneumoniae serotip 9 ≥ 5,2 log2 (*)
English: Actinobacillus pleuropneumoniae serotype 11 ≥ 4'9 log2 (*)
Slovenian: Actinobacillus pleuropneumoniae serotip 11 ≥ 4'9 log2 (*)
English: The potency test for P. multocida should be able to distinguish potent and subpotent batches.
Slovenian: Preskus učinkovitosti za komponento P. multocida mora dokazati razlike med serijami s primerno in manj primerno učinkovitostjo.
English: Pregnant sows:
Slovenian: Breje svinje:
English: Booster: One injection 2-3 weeks before each farrowing.
Slovenian: Poživitveni odmerek: eno injiciranje 2-3 tedne pred pričakovano kotitvijo
English: GROUNDS FOR REFUSAL OF THE GRANTING OF THE MARKETING AUTHORISATIONS SUSPENSION OF THE MARKETING AUTHORISATION
Slovenian: PODLAGA ZA ZAVRNITEV ODOBRITVE DOVOLJENJ ZA PROMET Z ZDRAVILOM IN ZADRŽANJE DOVOLJENJA ZA PROMET Z ZDRAVILOM
English: The lack of convincing data in support of the efficacy of P.multocida was considered a particular weakness.
Slovenian: Za posebno slabost se je štelo pomanjkanje prepričljivih podatkov v podporo učinkovitosti komponente P. multocida.
English: There are two points for particular discussion, firstly that challenge has not been done with APP Serotype 11, and secondly that because efficacy of the P.multocida component is based principally on field data there are no information on the precise specifications of the batches used.
Slovenian: Drugič, ker učinkovitost komponente P. multocida v glavnem temelji na terenskih podatkih, ni podatkov o natančnih specifikacijah za uporabljene serije.
English: The frequency of isolations of each organism in unvaccinated pigs provided some indication of the prevalence of the agent at the site and, taken in association with experience of pathology, could be considered to provide some support for the classification process.
Slovenian: Pogostnost osamitev posameznega organizma pri necepljenih prašičih do neke mere kaže lokalno pogostnost povzročitelja.
English: This was in part supported by the view that since P.multocida is a secondary infection that any possible benefits seen could equally well be attributed to a reduction of incidence of disease caused by the primary agent (A.pleuropneumoniae) afforded by vaccination against APP.
Slovenian: To delno podpira mnenje, da je P. multocida povzročitelj sekundarnih okužb in bi se lahko vsi možni koristni učinki enako verjetno pripisali zmanjšanju pojavnosti bolezni, povzročene s primarnim povzročiteljem (A. pleuropneumoniae), ki jo zagotovimo s cepljenjem proti APP. Glede na ta dejstva je Odbor zaključil, da učinkovitost komponente P. multocida serotipa A ni bila zadostno dokazana, zato mora biti v odsotnosti dokazanih koristi vsaka analiza tveganja in koristnih učinkov obvezno negativna.
English: First injection 4-5 weeks before expected farrowing.
Slovenian: Prvo injiciranje 4-5 tednov pred pričakovano kotitvijo Drugo injiciranje najmanj 2 tedna pred pričakovano kotitvijo
English: Slovak
Slovenian: Poljska
English: Strains of Actinobacillus pleuropneumoniae producing Apx I, ApxII and ApxIII toxins:
Slovenian: Sevi Actinobacillus pleuropneumoniae, ki tvorijo toksine Apx I, ApxII in ApxIII: Actinobacillus pleuropneumoniae serotip 2 ≥ 4'8 log2 (*)
English: Date of first authorisation: 11 November 2013 Date of latest renewal: 8 June 2018
Slovenian: Datum prve odobritve: 11. november 2013 Datum zadnjega podaljšanja: 8. junij 2018
English: Experience with Corbilta in patients under 18 years is limited.
Slovenian: Izkušnje z zdravilom Corbilta pri bolnikih, starih manj kot 18 let, so omejene.
English: You should be aware that Corbilta may make these reactions worse.
Slovenian: Zavedati se morate, da lahko zdravilo Corbilta te reakcije še poslabša.
English: Your doctor may take some regular laboratory tests during a long term treatment with Corbilta.
Slovenian: Zdravnik lahko izvede nekaj rednih laboratorijskih preiskav med dolgoročnim zdravljenjem z zdravilom Corbilta.
English: Paediatric population: The safety and efficacy of Corbilta in children aged below 18 years have not been established.
Slovenian: Pediatrična populacija: Varnost in učinkovitost zdravila Corbilta pri otrocih starih do 18 let nista bili dokazani.
English: Therefore, do not take Corbilta and iron supplements at the same time.
Slovenian: Zato ne jemljite zdravila Corbilta in železovih dodatkov sočasno.
English: However, caution should be exercised when these medicinal products are used concomitantly with Corbilta (see sections 4.3 and 4.4).
Slovenian: Vseeno pa je potrebna previdnost, kadar se ta zdravila uporabljajo sočasno z zdravilom Corbilta (glejte poglavji 4.3 in 4.4).
English: Corbilta should not be used during pregnancy unless the benefits for the mother outweigh the possible risks to the foetus.
Slovenian: Zdravila Corbilta ne smete uporabljati pri nosečnicah, razen če koristi za mater ne odtehtajo morebitnega tveganja za plod.
English: The starting dose of Corbilta should provide either the same amount of levodopa or slightly (5-10%) more.
Slovenian: Začetni odmerek zdravila Corbilta naj zagotavlja enako ali nekoliko (5-10 %) večjo količino levodope.
English: The CHMP agrees with the scientific conclusions made by the PRAC.The CHMP agrees with the scientific conclusions made by the PRAC.
Slovenian: Odbor CHMP se strinja z znanstvenimi zaključki odbora PRAC.
English: For some patients, Corbilta may not be well absorbed if it is taken with, or shortly after eating protein-rich food (such as meats, fish, dairy products, seeds and nuts).
Slovenian: Pri nekaterih bolnikih se zdravilo Corbilta ne absorbira tako dobro, če ga jemljejo med obrokom ali kmalu po obroku proteinsko bogate hrane (npr. meso, ribe, mlečni izdelki, semena in oreški).
English: Other medicines and Corbilta
Slovenian: Druga zdravila in zdravilo Corbilta
English: If you must undergo surgery, please tell your doctor that you are using Corbilta.
Slovenian: Če morate na operacijo, povejte svojemu zdravniku, da jemljete zdravilo Corbilta.
English: Corbilta with food and drink
Slovenian: Zdravilo Corbilta skupaj s hrano in pijačo
English: Corbilta may have a major influence on the ability to drive and use machines.
Slovenian: Zdravilo Corbilta ima pomemben vpliv na sposobnost vožnje in upravljanja strojev.
English: - All patients treated with Corbilta should be monitored carefully for the development of mental changes, depression with suicidal tendencies, and other serious antisocial behaviour.
Slovenian: - Vse bolnike, ki se zdravijo z zdravilom Corbilta, je treba skrbno spremljati, če bi prišlo do psihičnih sprememb, depresije s samomorilnimi nagnjenji ter drugih resnih oblik antisocialnega vedenja.
English: What Corbilta is and what it is used for
Slovenian: Kaj je zdravilo Corbilta in za kaj ga uporabljamo
English: Corbilta may lower your blood pressure, which may make you feel light-headed or dizzy.
Slovenian: Zdravilo Corbilta lahko zniža vaš krvni tlak, zaradi česar se boste počutili vrtoglavi in omotični.
English: In the pharmacokinetic studies with Corbilta the bioavailability of levodopa is higher in women than in men, primarily due to the difference in body weight, while there is no gender difference with carbidopa and entacapone.
Slovenian: V raziskavah farmakokinetike zdravila Corbilta je biološka uporabnost levodope pri ženskah večja kot pri moških predvsem zaradi razlike v telesni masi, medtem ko pri karbidopi in entakaponu razlike med spoloma ni bilo.
English: What you need to know before you take Corbilta
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Corbilta
English: 5 How to store Corbilta Contents of the pack and other information
Slovenian: 5 Shranjevanje zdravila Corbilta Vsebina pakiranja in dodatne informacije
English: When used with Corbilta, the daily dose of selegiline should not exceed 10 mg.
Slovenian: Ob sočasni uporabi z zdravilom Corbilta skupni dnevni odmerek selegilina ne sme presegati 10 mg.
English: If you have accidentally taken more Corbilta tablets than you should, talk to your doctor or pharmacist immediately.
Slovenian: Če ste po naključju vzeli več tablet zdravila Corbilta, kot bi smeli, se nemudoma posvetujte s svojim zdravnikom ali farmacevtom.
English: Therefore, the use of Corbilta in children or adolescents is not recommended.
Slovenian: Zato se uporaba zdravila Corbilta pri otrocih ali mladostnikih ne priporoča.
English: - Corbilta contains sucrose, and therefore patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Slovenian: - Zdravilo Corbilta vsebuje saharozo, zato bolniki z redkimi prirojenimi motnjami, kot so intoleranca za fruktozo, malabsorpcija glukoze-galaktoze ali pomanjkanje saharaze-izomaltaze, ne smejo jemati tega zdravila.
English: Do not take Corbilta if you are taking certain medicines for treating depression (combinations of selective MAO-A and MAO-B inhibitors, or non-selective MAO inhibitors).
Slovenian: Ne uporabljajte zdravila Corbilta, če jemljete nekatera zdravila za zdravljenje depresije (kombinacija selektivnih zaviralcev MAO-A in MAO-B ali neselektivnih zaviralcev MAO).
English: Corbilta is used for the treatment of Parkinson's disease.
Slovenian: Zdravilo Corbilta se uporablja za zdravljenje Parkinsonove bolezni.
English: What Corbilta is and what it is used for What you need to know before you take Corbilta How to take Corbilta
Slovenian: Kaj je zdravilo Corbilta in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Corbilta Kako jemati zdravilo Corbilta Možni neželeni učinki
English: Pyridoxine, however, is not effective in reversing the actions of Corbilta.
Slovenian: Vendar pa piridoksin ni učinkovit kot protisredstvo za delovanje zdravila Corbilta.
English: - Corbilta is not recommended for the treatment of drug-induced extrapyramidal reactions.
Slovenian: - Zdravilo Corbilta se ne priporoča za zdravljenje ekstrapiramidnih reakcij, ki jih povzročajo zdravila.
English: - If general anaesthesia is required, therapy with Corbilta may be continued for as long as the patient is permitted to take fluids and medicinal products by mouth.
Slovenian: - Če je potrebna splošna anestezija, se lahko terapija z zdravilom Corbilta nadaljuje vse dokler sme bolnik jemati tekočine in zdravila peroralno.
English: It may therefore be necessary, particularly in patients with dyskinesia, to reduce levodopa dose by 10-30% within the first days to first weeks after initiating Corbilta treatment.
Slovenian: Zato bo morda potrebno v prvih dneh oziroma prvih tednih po uvedbi zdravljenja z zdravilom Corbilta, zlasti pri bolnikih z diskinezijo zmanjšati odmerek levodope za 10-30 %.
English: Corbilta may increase the effects and side effects of certain medicines.
Slovenian: Zdravilo Corbilta lahko poveča učinke in neželene učinke določenih zdravil.
English: Other forms of interactions: Since levodopa competes with certain amino acids, the absorption of Corbilta may be impaired in some patients on high protein diet.
Slovenian: Druge oblike interakcij: Ker levodopa tekmuje (kompetitira) z nekaterimi aminokislinami, je lahko pri nekaterih bolnikih, ki uživajo visoko proteinsko dieto, absorpcija zdravila Corbilta motena.
English: Therefore, Corbilta and iron preparations should be taken at least 2-3 hours apart (see section 4.8).
Slovenian: Zato je treba pri jemanju zdravila Corbilta in železovih pripravkov upoštevati najmanj 2-3 urni razmak med obema zdraviloma (glejte poglavje 4.8).
English: Other antiparkinsonian medicinal products: To date there has been no indication of interactions that would preclude concurrent use of standard antiparkinsonian medicinal products with Corbilta therapy.
Slovenian: Drugi antiparkinsoniki: Do sedaj niso znane nobene interakcije, ki bi omejevale sočasno uporabo standardnih antiparkinsonikov in zdravila Corbilta.
English: Corbilta contains three active substances (levodopa, carbidopa and entacapone) in one film-coated tablet.
Slovenian: Zdravilo Corbilta vsebuje tri učinkovine (levodopo, kabidopo in entakapon) v eni filmsko obloženi tableti.
English: Tell your doctor if you or your family/carer notices you are developing addiction-like symptoms leading to craving for large doses of Corbilta and other medicines used to treat Parkinson's disease.
Slovenian: Obvestite zdravnika, če vi ali kdo od družinskih članov/negovalec opazi(te), da se pri vas razvijajo simptomi, podobni odvisnosti, ki vodijo do potrebe po velikih odmerkih zdravila Corbilta in drugih zdravil za zdravljenje Parkinsonove bolezni.
English: - Patients with chronic wide-angle glaucoma may be treated with Corbilta with caution, provided the intra-ocular pressure is well controlled and the patient is monitored carefully for changes in intra-ocular pressure.
Slovenian: - Bolniki s kroničnim glavkomom odprtega zakotja se ob primerni previdnosti lahko zdravijo z zdravilom Corbilta, pod pogojem, da je intraokularni tlak dobro obvladovan in da bolnika skrbno spremljamo, če bi se pojavile spremembe v intraokularnem tlaku.
English: At the initiation, Corbilta should be adjusted to correspond as closely as possible to the total daily dose of levodopa currently used.
Slovenian: Ob uvedbi zdravljenja je treba zdravilo Corbilta prilagoditi tako, da kar najbolj odgovarja skupnemu do sedaj uporabljanemu dnevnemu odmerku levodope.